

Practice Changing Data from 2023: Hematologic Malignancies

Mazie Tsang, MD, MAS, MS

Disclosures

- I specialize in lymphoid malignancies.
- Stock ownership: Poseida Therapeutics
- Advisory board: Novartis

Objectives


To review the FDA updates and pivotal trials from 2023 for:

1. Lymphoid Malignancies
2. Acute Leukemia
3. Myeloma

Lymphoid Malignancies




Lymphoma and Chronic Lymphocytic Leukemia

Bispecific T-cell Engagers




Phase 1/2 Glofitamab for R/R DLBCL (FDA Approved)

- Population: R/R DLBCL (after ≥ 2 prior lines), N=154
- Intervention: Glofitamab IV
- Comparison: None
- Outcome: ORR 52%, CR 39%, median time to response was 42 days



Phase 1/2 EPCORE NHL-1: Epcoritamab in R/R DLBCL (FDA Approved)



- Population: R/R DLBCL (after ≥ 2 prior lines), N=157
- Intervention: Epcoritamab SC
- Comparison: None
- Outcome: ORR 63%, CR 39%, median DOR 12 months, median time to response 1.4 months



Thieblemont et al. JCO 2023 Apr 20;41(12):2238-2247


Phase 3 ALPINE: Zanubrutinib for R/R CLL/SLL (FDA Approved)

- Population: R/R CLL/SLL
- Intervention: Zanubrutinib
- Comparison: Ibrutinib (1:1)
- Outcome: ORR 83.5% in zanubrutinib vs 74.2% in ibrutinib arm



JR Brown et al. N Engl J Med 2023;388:319-332


B Progression-free Survival, Population with Chromosome 17p Deletion, TP53 Mutation, or Both



No. at Risk

Zanutrutinib	75	71	68	66	64	61	56	47	32	30	21	18	3	0
Ibrutinib	75	70	68	59	55	48	45	34	19	17	10	9	2	0

C Overall Survival




No. at Risk

Zanutrutinib	327	319	313	310	303	298	287	268	224	185	169	134	56	8	0
Ibrutinib	325	314	307	297	290	283	271	255	200	171	156	124	50	7	3

JR Brown et al. N Engl J Med 2023;388:319-332


Phase 1/2 BRUIN: Pirtobrutinib in R/R Mantle Cell (FDA Approved)

- Population: R/R MCL prior BTKi, N=120 (phase 2)
- Intervention: Pirtobrutinib 200 mg daily
- Comparison: None
- Outcome: ORR 50%, CR 13%, median DOR 8.3 months



Mato et al. Lancet 2021 Mar 6;397(10277): 892-901

Phase 3 POLARIX: Polatuzumab + R-CHP for New DLBCL or HGBL (FDA Approved)




- **Population:** New intermediate- or high-risk DLBCL, N=879
- **Intervention:** Pola-R-CHP
- **Comparison:** 1:1, double-blind, placebo-controlled R-CHOP
- **Outcome:** At 2 years, PFS 76.7% in POLA-R-CHP vs 70.2% in R-CHOP group; no OS difference

H Tilly et al. N Engl J Med 2022;386:351-363

Phase 1/2 TRANSCEND CLL 004: R/R CLL/SLL

- Population: R/R CLL/SLL (≥ 2 prior lines), N=117
- Intervention: Lisocabtagene maraleucel
- Comparison: None
- Outcome: CR 18%, ORR 43%, median DOR 35 mo
- Deaths: 43/51 after liso-cel infusion




Siddiqi et al. Lancet 2023; 402: 641-54

Practice Changing Data from 2023: Hematologic Malignancies

Acute Leukemia

Phase 3 QuANTUM-First: Quizartinib for FLT3-ITD positive AML (FDA Approved)

- Population: Newly diagnosed FLT3-ITD positive AML, N=539
- Intervention: Quizartinib + standard induction and consolidation, and quizartinib as maintenance
- Comparator: 1:1 double-blinded, placebo-controlled trial
- Outcome: Median OS 31.9 mo for quizartinib vs 15.1 mo for placebo




Erba et al. Lancet 2023 May 13;401(10388): 1571-1583

Practice Changing Data from 2023: Hematologic Malignancies

Multiple Myeloma

Phase 1 MonumenTAL-1: Talquetamab (GPRC5D-CD3 T-cell engager) in R/R MM (FDA Approved)




- Population: R/R MM (after >4 prior lines), N=187
- Intervention: Single-arm open label talquetamab 0.4 mg/kg subcutaneous weekly or 0.8 mg/kg subcutaneous every other week
- Comparator: None
- Outcome: For 0.4 mg/kg, ORR 73% with median DOR 9.5 months. For 0.8 mg/kg, ORR 73.6%, median DOR not estimated

A Chari et al. N Engl J Med 2022;387:2232-2244

Phase 2 MagnetisMM-3: Elranatamab in R/R MM (FDA Approved)

Figure: OS in overall cohort (red) and patients with >CR (blue)




- **Population:** R/R MM (after ≥ 4 prior lines), N=123
- **Intervention:** Subcutaneous elranatamab weekly after two step-up doses; biweekly if responding
- **Comparator:** None
- **Outcome:** ORR 61%, 35% \geq complete response. Duration of response 90.4% at 6 months and 82.3% at 9 months

Lesokhin et al. Nat Med 29: 2259-2267 (2023)

Phase 3 CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide Refractory MM

- Population: Lenalidomide-refractory MM (after 3 prior lines), N=419
- Intervention: 1:1 randomization single cilta-cel infusion after bridging therapy
- Comparison: SOC (physician's choice PVd or DPd)
- Outcomes: Cilta-cel (median PFS not reached, ORR 84.6%, CR 73.1%) vs. SOC (median PFS 11.8 mo, ORR 67.3%, CR 21.8%)



J San-Miguel et al. N Engl J Med 2023;389:335-347

Thank You, LEAD!



SCOTTSDALE, AZ
OCT 13 - 14
2023

What to expect at
LEAD 2023

LEAD Bio Ascend LEAD Bio Ascend LEAD

Bio Ascend LEAD Bio Ascend LEAD Bio Ascend LEAD Bio Ascend

THE WOLFPACK
#HowtG

XLEAD2019

LEADoncology.com | #LEAD2023

The image shows a promotional poster for the 5th Annual LEAD 2023 conference. The top section features the event details: 'SCOTTSDALE, AZ' in a circular graphic, 'OCT 13 - 14 2023' in a purple circle, and the main title 'What to expect at LEAD 2023'. Below this is a repeating pattern of 'LEAD Bio Ascend' logos. The bottom half of the poster is a group photograph of approximately 20 women, many wearing name tags. Two women in the center are holding a white sign that reads 'THE WOLFPACK #HowtG'. Another woman in the front row is holding a sign that says 'XLEAD2019'. The background of the photo is a white wall with 'LEAD Bio Ascend' logos. At the bottom of the poster is an orange banner with the text 'LEADoncology.com | #LEAD2023'.



5th Annual
LEAD 2023
Enriching Experiences for Women in Hematology & Oncology

“I attended LEAD last year and it was great! Wonderful people and refreshing agenda. Highly recommended.”
- 2022 attendee

LEADoncology.com | #LEAD2023

The image features a testimonial for the LEAD 2023 conference. At the top right, it says '5th Annual LEAD 2023 Enriching Experiences for Women in Hematology & Oncology'. Below this is a quote in a teal speech bubble: '“I attended LEAD last year and it was great! Wonderful people and refreshing agenda. Highly recommended.” - 2022 attendee'. The bottom half of the image is a group photograph of about 10 women smiling and posing together. They are dressed in professional attire. At the bottom of the image is an orange banner with the text 'LEADoncology.com | #LEAD2023'.